Suzetrigine · diabetic-neuropathy Phase 3
Vertex guides to enrollment completion by year-end 2026. That is not a Phase 3 result date. Acute-pain approval does not establish efficacy in diabetic peripheral neuropathic pain. suzetrigine — phase 3 study in Diabetic Peripheral Neuropathic Pain. NCT06628908 measures Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo (From Baseline up to Week 12). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Enrollment milestone in 2026 — readout unconfirmed
Potential outcome market
Will suzetrigine meet the prespecified primary endpoint in NCT06628908 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.